Does the media favor TARS or CRMD?

In the previous week, Tarsus Pharmaceuticals had 3 more articles in the media than CorMedix. MarketBeat recorded 7 mentions for Tarsus Pharmaceuticals and 4 mentions for CorMedix. Tarsus Pharmaceuticals' average media sentiment score of 0.43 beat CorMedix's score of 0.42 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tarsus Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CorMedix 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor CRMD or RARE?

In the previous week, CorMedix had 1 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 4 mentions for CorMedix and 3 mentions for Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical's average media sentiment score of 1.73 beat CorMedix's score of 0.42 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CorMedix 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Ultragenyx Pharmaceutical 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has stronger valuation and earnings, IRON or CRMD?

CorMedix has higher revenue and earnings than Disc Medicine. Disc Medicine is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Disc Medicine N/A N/A -$212.18M -$6.62 N/A CorMedix $311.71M 1.98 $163.05M $2.13 3.69

Is IRON or CRMD more profitable?

CorMedix has a net margin of 45.25% compared to Disc Medicine's net margin of 0.00%. CorMedix's return on equity of 45.57% beat Disc Medicine's return on equity. Company Net Margins Return on Equity Return on Assets Disc Medicine N/A -36.94% -33.88% CorMedix 45.25% 45.57% 24.76%

Does the media refer more to IRON or CRMD?

In the previous week, Disc Medicine had 9 more articles in the media than CorMedix. MarketBeat recorded 13 mentions for Disc Medicine and 4 mentions for CorMedix. CorMedix's average media sentiment score of 0.42 beat Disc Medicine's score of 0.18 indicating that CorMedix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Disc Medicine 3 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CorMedix 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer VERA or CRMD?

In the previous week, Vera Therapeutics had 1 more articles in the media than CorMedix. MarketBeat recorded 5 mentions for Vera Therapeutics and 4 mentions for CorMedix. Vera Therapeutics' average media sentiment score of 0.51 beat CorMedix's score of 0.42 indicating that Vera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vera Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CorMedix 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer TRVI or CRMD?

In the previous week, CorMedix had 1 more articles in the media than Trevi Therapeutics. MarketBeat recorded 4 mentions for CorMedix and 3 mentions for Trevi Therapeutics. Trevi Therapeutics' average media sentiment score of 0.47 beat CorMedix's score of 0.42 indicating that Trevi Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trevi Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CorMedix 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

CorMedix (CRMD) Competitors

$7.85 +0.13 (+1.68%)

Closing price 06/26/2026 04:00 PM Eastern

Extended Trading

$7.81 -0.04 (-0.51%)

As of 06/26/2026 07:49 PM Eastern

Compare

CRMD vs. TARS, RARE, IRON, VERA, and TRVI

Should you buy CorMedix stock or one of its competitors? MarketBeat compares CorMedix with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CorMedix include Tarsus Pharmaceuticals (TARS), Ultragenyx Pharmaceutical (RARE), Disc Medicine (IRON), Vera Therapeutics (VERA), and Trevi Therapeutics (TRVI). These companies are all part of the "pharmaceutical products" industry.

How does CorMedix compare to Tarsus Pharmaceuticals?

Tarsus Pharmaceuticals (NASDAQ:TARS) and CorMedix (NASDAQ:CRMD) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. Comparatively, 34.2% of CorMedix shares are held by institutional investors. 9.6% of Tarsus Pharmaceuticals shares are held by company insiders. Comparatively, 3.5% of CorMedix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

CorMedix has lower revenue, but higher earnings than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tarsus Pharmaceuticals	$451.36M	6.00	-$66.42M	-$1.14	N/A
CorMedix	$311.71M	1.98	$163.05M	$2.13	3.69

Tarsus Pharmaceuticals currently has a consensus target price of $90.67, suggesting a potential upside of 44.10%. CorMedix has a consensus target price of $15.00, suggesting a potential upside of 91.08%. Given CorMedix's higher possible upside, analysts clearly believe CorMedix is more favorable than Tarsus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Tarsus Pharmaceuticals had 3 more articles in the media than CorMedix. MarketBeat recorded 7 mentions for Tarsus Pharmaceuticals and 4 mentions for CorMedix. Tarsus Pharmaceuticals' average media sentiment score of 0.43 beat CorMedix's score of 0.42 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tarsus Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CorMedix	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

CorMedix has a net margin of 45.25% compared to Tarsus Pharmaceuticals' net margin of -9.02%. CorMedix's return on equity of 45.57% beat Tarsus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tarsus Pharmaceuticals	-9.02%	-14.19%	-8.89%
CorMedix	45.25%	45.57%	24.76%

Tarsus Pharmaceuticals has a beta of 0.49, indicating that its stock price is 51% less volatile than the broader market. Comparatively, CorMedix has a beta of 1.46, indicating that its stock price is 46% more volatile than the broader market.

Summary

CorMedix beats Tarsus Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does CorMedix compare to Ultragenyx Pharmaceutical?

CorMedix (NASDAQ:CRMD) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, risk, institutional ownership, profitability, valuation and earnings.

CorMedix has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CorMedix	$311.71M	1.98	$163.05M	$2.13	3.69
Ultragenyx Pharmaceutical	$673M	4.50	-$575M	-$6.11	N/A

34.2% of CorMedix shares are owned by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. 3.5% of CorMedix shares are owned by company insiders. Comparatively, 5.2% of Ultragenyx Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, CorMedix had 1 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 4 mentions for CorMedix and 3 mentions for Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical's average media sentiment score of 1.73 beat CorMedix's score of 0.42 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CorMedix	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ultragenyx Pharmaceutical	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

CorMedix currently has a consensus price target of $15.00, indicating a potential upside of 91.08%. Ultragenyx Pharmaceutical has a consensus price target of $59.56, indicating a potential upside of 93.57%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher possible upside, analysts clearly believe Ultragenyx Pharmaceutical is more favorable than CorMedix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.82

CorMedix has a beta of 1.46, suggesting that its share price is 46% more volatile than the broader market. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.37, suggesting that its share price is 63% less volatile than the broader market.

CorMedix has a net margin of 45.25% compared to Ultragenyx Pharmaceutical's net margin of -91.03%. CorMedix's return on equity of 45.57% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CorMedix	45.25%	45.57%	24.76%
Ultragenyx Pharmaceutical	-91.03%	-1,024.42%	-45.78%

Summary

Ultragenyx Pharmaceutical beats CorMedix on 9 of the 17 factors compared between the two stocks.

How does CorMedix compare to Disc Medicine?

Disc Medicine (NASDAQ:IRON) and CorMedix (NASDAQ:CRMD) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

CorMedix has higher revenue and earnings than Disc Medicine. Disc Medicine is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Disc Medicine	N/A	N/A	-$212.18M	-$6.62	N/A
CorMedix	$311.71M	1.98	$163.05M	$2.13	3.69

Disc Medicine presently has a consensus target price of $105.80, indicating a potential upside of 41.48%. CorMedix has a consensus target price of $15.00, indicating a potential upside of 91.08%. Given CorMedix's higher probable upside, analysts clearly believe CorMedix is more favorable than Disc Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75

Disc Medicine has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market. Comparatively, CorMedix has a beta of 1.46, indicating that its stock price is 46% more volatile than the broader market.

83.7% of Disc Medicine shares are owned by institutional investors. Comparatively, 34.2% of CorMedix shares are owned by institutional investors. 3.8% of Disc Medicine shares are owned by insiders. Comparatively, 3.5% of CorMedix shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Disc Medicine had 9 more articles in the media than CorMedix. MarketBeat recorded 13 mentions for Disc Medicine and 4 mentions for CorMedix. CorMedix's average media sentiment score of 0.42 beat Disc Medicine's score of 0.18 indicating that CorMedix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Disc Medicine	3 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CorMedix	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

CorMedix has a net margin of 45.25% compared to Disc Medicine's net margin of 0.00%. CorMedix's return on equity of 45.57% beat Disc Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Disc Medicine	N/A	-36.94%	-33.88%
CorMedix	45.25%	45.57%	24.76%

Summary

CorMedix beats Disc Medicine on 10 of the 14 factors compared between the two stocks.

How does CorMedix compare to Vera Therapeutics?

Vera Therapeutics (NASDAQ:VERA) and CorMedix (NASDAQ:CRMD) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

99.2% of Vera Therapeutics shares are held by institutional investors. Comparatively, 34.2% of CorMedix shares are held by institutional investors. 15.9% of Vera Therapeutics shares are held by company insiders. Comparatively, 3.5% of CorMedix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Vera Therapeutics had 1 more articles in the media than CorMedix. MarketBeat recorded 5 mentions for Vera Therapeutics and 4 mentions for CorMedix. Vera Therapeutics' average media sentiment score of 0.51 beat CorMedix's score of 0.42 indicating that Vera Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vera Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CorMedix	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Vera Therapeutics has a beta of 0.93, meaning that its stock price is 7% less volatile than the broader market. Comparatively, CorMedix has a beta of 1.46, meaning that its stock price is 46% more volatile than the broader market.

Vera Therapeutics currently has a consensus price target of $78.00, indicating a potential upside of 83.70%. CorMedix has a consensus price target of $15.00, indicating a potential upside of 91.08%. Given CorMedix's higher possible upside, analysts plainly believe CorMedix is more favorable than Vera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75

CorMedix has a net margin of 45.25% compared to Vera Therapeutics' net margin of 0.00%. CorMedix's return on equity of 45.57% beat Vera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vera Therapeutics	N/A	-74.86%	-60.18%
CorMedix	45.25%	45.57%	24.76%

CorMedix has higher revenue and earnings than Vera Therapeutics. Vera Therapeutics is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.54	N/A
CorMedix	$311.71M	1.98	$163.05M	$2.13	3.69

Summary

CorMedix beats Vera Therapeutics on 9 of the 14 factors compared between the two stocks.

How does CorMedix compare to Trevi Therapeutics?

Trevi Therapeutics (NASDAQ:TRVI) and CorMedix (NASDAQ:CRMD) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, analyst recommendations and earnings.

CorMedix has a net margin of 45.25% compared to Trevi Therapeutics' net margin of 0.00%. CorMedix's return on equity of 45.57% beat Trevi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trevi Therapeutics	N/A	-24.53%	-23.37%
CorMedix	45.25%	45.57%	24.76%

CorMedix has higher revenue and earnings than Trevi Therapeutics. Trevi Therapeutics is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.32	N/A
CorMedix	$311.71M	1.98	$163.05M	$2.13	3.69

Trevi Therapeutics has a beta of 1.04, indicating that its stock price is 4% more volatile than the broader market. Comparatively, CorMedix has a beta of 1.46, indicating that its stock price is 46% more volatile than the broader market.

Trevi Therapeutics presently has a consensus target price of $22.90, indicating a potential upside of 26.17%. CorMedix has a consensus target price of $15.00, indicating a potential upside of 91.08%. Given CorMedix's higher possible upside, analysts clearly believe CorMedix is more favorable than Trevi Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, CorMedix had 1 more articles in the media than Trevi Therapeutics. MarketBeat recorded 4 mentions for CorMedix and 3 mentions for Trevi Therapeutics. Trevi Therapeutics' average media sentiment score of 0.47 beat CorMedix's score of 0.42 indicating that Trevi Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trevi Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CorMedix	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

95.8% of Trevi Therapeutics shares are held by institutional investors. Comparatively, 34.2% of CorMedix shares are held by institutional investors. 18.3% of Trevi Therapeutics shares are held by company insiders. Comparatively, 3.5% of CorMedix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

CorMedix beats Trevi Therapeutics on 10 of the 16 factors compared between the two stocks.

Get CorMedix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRMD vs. The Competition

Export

Metric	CorMedix	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$615.85M	$3.63B	$7.04B	$12.19B
Dividend Yield	N/A	2.21%	2.66%	6.23%
P/E Ratio	3.69	21.56	26.13	24.16
Price / Sales	1.98	334.26	556.13	101.82
Price / Cash	3.84	141.14	47.95	55.62
Price / Book	1.53	8.33	10.78	6.36
Net Income	$163.05M	$23.91M	$3.58B	$337.99M
7 Day Performance	-9.46%	3.42%	2.22%	0.10%
1 Month Performance	-7.21%	1.55%	1.12%	-0.11%
1 Year Performance	-37.20%	65.22%	34.29%	27.61%

CorMedix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRMD CorMedix	3.1311 of 5 stars	$7.85 +1.7%	$15.00 +91.1%	-47.5%	$615.85M	$311.71M	3.69	30	High Trading Volume
TARS Tarsus Pharmaceuticals	3.2964 of 5 stars	$63.56 +0.6%	$90.67 +42.6%	+56.0%	$2.72B	$451.36M	N/A	50	News Coverage
RARE Ultragenyx Pharmaceutical	3.8648 of 5 stars	$29.03 +5.8%	$59.56 +105.2%	-17.1%	$2.70B	$673M	N/A	1,371	Analyst Downgrade
IRON Disc Medicine	2.1214 of 5 stars	$70.80 +0.0%	$105.80 +49.4%	+38.1%	$2.70B	N/A	N/A	30	Insider Trade
VERA Vera Therapeutics	3.3118 of 5 stars	$38.43 +9.5%	$78.00 +103.0%	+82.3%	$2.52B	N/A	N/A	40	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRMD) was last updated on 6/27/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CorMedix (CRMD) Competitors

CRMD vs. TARS, RARE, IRON, VERA, and TRVI

How does CorMedix compare to Tarsus Pharmaceuticals?

Summary

How does CorMedix compare to Ultragenyx Pharmaceutical?

Summary

How does CorMedix compare to Disc Medicine?

Summary

How does CorMedix compare to Vera Therapeutics?

Summary

How does CorMedix compare to Trevi Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRMD vs. The Competition

CorMedix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CorMedix (CRMD) Competitors

CRMD vs. TARS, RARE, IRON, VERA, and TRVI

How does CorMedix compare to Tarsus Pharmaceuticals?

Do institutionals and insiders hold more shares of TARS or CRMD?

Which has preferable earnings & valuation, TARS or CRMD?

Do analysts recommend TARS or CRMD?

Does the media favor TARS or CRMD?

Is TARS or CRMD more profitable?

Which has more risk & volatility, TARS or CRMD?

Summary

How does CorMedix compare to Ultragenyx Pharmaceutical?

Which has better valuation and earnings, CRMD or RARE?

Do institutionals & insiders have more ownership in CRMD or RARE?

Does the media favor CRMD or RARE?

Do analysts prefer CRMD or RARE?

Which has more risk and volatility, CRMD or RARE?

Is CRMD or RARE more profitable?

Summary

How does CorMedix compare to Disc Medicine?

Which has stronger valuation and earnings, IRON or CRMD?

Do analysts rate IRON or CRMD?

Which has more risk & volatility, IRON or CRMD?

Do institutionals & insiders believe in IRON or CRMD?

Does the media refer more to IRON or CRMD?

Is IRON or CRMD more profitable?

Summary

How does CorMedix compare to Vera Therapeutics?

Do insiders & institutionals believe in VERA or CRMD?

Does the media prefer VERA or CRMD?

Which has more volatility and risk, VERA or CRMD?

Do analysts prefer VERA or CRMD?

Is VERA or CRMD more profitable?

Which has higher earnings and valuation, VERA or CRMD?

Summary

How does CorMedix compare to Trevi Therapeutics?

Is TRVI or CRMD more profitable?

Which has preferable valuation and earnings, TRVI or CRMD?

Which has more risk & volatility, TRVI or CRMD?

Do analysts prefer TRVI or CRMD?

Does the media prefer TRVI or CRMD?

Do insiders and institutionals believe in TRVI or CRMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRMD vs. The Competition

CorMedix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools